FDA approves third dose of Pfizer COVID-19 vaccine for the elderly

  • Share

The US Food and Drug Administration (FDA) on Wednesday (22/9) approved the Pfizer-BioNTech COVID-19 booster vaccine for those 65 years of age and older and some Americans who are at high risk. The move paves the way for accelerating the vaccination program.

Booster dose or booster will be given at least six months after the second dose. Groups eligible for injections booster also includes people most susceptible to severe disease and those whose occupations are at risk of being exposed to COVID-19, the FDA said.

The Centers for Disease Control and Prevention (CDC) advisory panel could vote Thursday on administering the third vaccine, an official said at the panel’s public meeting on Wednesday.

President Joe Biden announced in August that the government intends to roll out booster vaccinations for people aged 16 and older this week pending approval from the FDA and CDC.

Meanwhile, drugmaker Johnson & Johnson said Tuesday (21/9), administering a second dose of the COVID-19 vaccine has been shown to increase its effectiveness against moderate to severe symptoms of COVID-19 disease.

Information about Moderna Inc’s COVID-19 booster vaccine. will be announced in the next few weeks, said Dr. Anthony Fauci, President Joe Biden’s chief medical adviser, on Sunday (19/9). (ps/rs)

  • Share

Leave a Reply

Your email address will not be published. Required fields are marked *